<code id='DC4D624BC6'></code><style id='DC4D624BC6'></style>
    • <acronym id='DC4D624BC6'></acronym>
      <center id='DC4D624BC6'><center id='DC4D624BC6'><tfoot id='DC4D624BC6'></tfoot></center><abbr id='DC4D624BC6'><dir id='DC4D624BC6'><tfoot id='DC4D624BC6'></tfoot><noframes id='DC4D624BC6'>

    • <optgroup id='DC4D624BC6'><strike id='DC4D624BC6'><sup id='DC4D624BC6'></sup></strike><code id='DC4D624BC6'></code></optgroup>
        1. <b id='DC4D624BC6'><label id='DC4D624BC6'><select id='DC4D624BC6'><dt id='DC4D624BC6'><span id='DC4D624BC6'></span></dt></select></label></b><u id='DC4D624BC6'></u>
          <i id='DC4D624BC6'><strike id='DC4D624BC6'><tt id='DC4D624BC6'><pre id='DC4D624BC6'></pre></tt></strike></i>

          
          WSS
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion